KW-0761

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral T-cell Lymphoma

Conditions

Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma

Trial Timeline

Aug 1, 2010 → Sep 1, 2012

About KW-0761

KW-0761 is a phase 2 stage product being developed by Kyowa Kirin for Peripheral T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01226472. Target conditions include Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT01192984Phase 2Completed
NCT01226472Phase 2Completed
NCT00920790Phase 2Completed
NCT00888927Phase 1/2Completed
NCT00355472Phase 1Completed

Competing Products

20 competing products in Peripheral T-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
LY3857210 + PlaceboEli LillyPhase 2
52
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
52
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Valemetostat TosylateDaiichi SankyoPhase 2
52
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
52
QutenzaAstellas PharmaPre-clinical
23
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
85
Qutenza exposureAstellas PharmaPre-clinical
23
QUTENZAAstellas PharmaPhase 3
77
Qutenza + PregabalinAstellas PharmaApproved
85